[1] 李檬, 虞朝辉, 厉有名. 脂肪肝靶点新启示:关注3-巯基丙酮酸转硫酶/硫化氢通路. 中华内科杂志, 2019, 58(3):220-220. [2] Sivell C. Nonalcoholic fatty liver disease: a silent epidemic. Gastroenterol Nurs, 2019,42(5):428-434. [3] Staufer K, Halilbasic E, Spindelboeck W, et al. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. Unit Eur Gastroenterol J, 2019, 7(8):1113-1123. [4] Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int, 2019, 13(6):674-687. [5] 王珊, 张健, 蒋晓忠, 等.非肥胖人群的腰围轨迹与新发非酒精性脂肪肝的相关性. 中华流行病学杂志, 2020, 41(6):824-828. [6] Abenavoli L, Boccuto L, Federico A, etal. Diet and non-alcoholic fatty liver disease: the Mediterranean way. Int J Environ Res Public Health, 2019,16(17):3011-3018. [7] Pennisi G, Celsa C, Spatola F, et al. Pharmacological therapy of non-alcoholic fatty liver disease: what drugs are availablenow and future perspectives. Int J Environ Res Public Health, 2019, 16(22):4334-4341. [8] Fernando DH, Forbes JM, Angus PW, et al. Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products. Int J Mol Sci,2019, 20(20):5037-5043. [9] Ko JS. New perspectives in pediatric nonalcoholic fatty liver disease: epidemiology, genetics, diagnosis, and natural history. Pediatr Gastroenterol Hepatol Nutr, 2019, 22(6):501-510. [10] Baratta F, Pastori D, Ferro D, et al. Reduced lysosomal acid lipase activity: a new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease. World J Gastroenterol, 2019, 25(30):4172-4180. [11] Pennisi G, Celsa C, Giammanco A, et al. The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: screening issue and future perspectives. Int J Mol Sci, 2019, 20(22):5613-5619. [12] Lee C, Kim J, Jung Y. Potential therapeutic application of estrogen in gender disparity of nonalcoholic fattyliver disease/nonalcoholic steatohepatitis. Cells, 2019, 8(10):1259-1267. [13] Riazi K, Raman M, Taylor L, et al. Dietary patterns and components in nonalcoholic fatty liver disease (NAFLD): what key messages can health care providers offer? Nutrients, 2019, 11(12):2878-2885. [14] Recaredo G, Marin-Alejandre BA, Cantero I, et al. Association between different animal protein sources and liver status in obese subjects with non-alcoholic fatty liver disease: fatty liver in obesity (FLiO) study. Nutrients, 2019, 11(10):2359-2364. [15] Marin-Alejandre BA, Abete I, Cantero I, et al. The metabolic and hepatic impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: the fatty liver in obesity (FLiO) randomized controlledtrial. Nutrients, 2019,11(10):2543. [16] Kang BK, Kim M, Shin SJ, et al. Correlation of clinical and histopathologic parameters with ultrasonographic grades in pediatric non-alcoholic fatty liver disease. J Korean Med Sci, 2019, 34(47):298-306. [17] Di Costanzo A, Pacifico L, D'Erasmo L, et al. Nonalcoholic fatty liver disease (NAFLD), but not its susceptibility gene variants, influences the decrease of kidney function in overweight/obese children. Int J Mol Sci, 2019, 20(18):4444-4450. [18] Nicoletti A, Ponziani FR, Biolato M, et al. Intestinal permeability in the pathogenesis of liver damage: from non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol, 2019, 25(33):4814-4834. [19] Federico A, Dallio M, Masarone M, et al. Evaluation of the effect derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients. Oxid Med Cell Longev, 2019, 20(19):874-881. [20] Liu J, Wang T, He K, et al. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation. Eur Rev Med Pharmacol Sci, 2019,23(18):8158-8167. |